Ranger Investment Management L.P. Makes New $12.20 Million Investment in Charles River Laboratories International, Inc. $CRL

Posted by Brenda Bartman on Jul 29th, 2026

Ranger Investment Management L.P. bought a new stake in shares of Charles River Laboratories International, Inc. (NYSE:CRL – Free Report) in the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund bought 70,715 shares of the medical research company’s stock, valued at approximately $12,198,000.

Other institutional investors and hedge funds also recently modified their holdings of the company. Vanguard Group Inc. boosted its holdings in shares of Charles River Laboratories International by 0.8% in the 4th quarter. Vanguard Group Inc. now owns 5,887,175 shares of the medical research company’s stock valued at $1,174,374,000 after buying an additional 47,432 shares during the period. Invesco Ltd. grew its position in shares of Charles River Laboratories International by 115.8% during the 4th quarter. Invesco Ltd. now owns 2,696,150 shares of the medical research company’s stock valued at $537,828,000 after buying an additional 1,446,972 shares during the last quarter. State Street Corp raised its stake in Charles River Laboratories International by 2.2% during the fourth quarter. State Street Corp now owns 1,871,688 shares of the medical research company’s stock worth $373,364,000 after acquiring an additional 40,535 shares during the period. Dimensional Fund Advisors LP raised its stake in Charles River Laboratories International by 14.6% during the first quarter. Dimensional Fund Advisors LP now owns 1,652,484 shares of the medical research company’s stock worth $285,001,000 after acquiring an additional 210,260 shares during the period. Finally, Geode Capital Management LLC lifted its holdings in Charles River Laboratories International by 0.8% in the fourth quarter. Geode Capital Management LLC now owns 1,276,502 shares of the medical research company’s stock worth $254,186,000 after acquiring an additional 9,756 shares during the last quarter. 98.91% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other Charles River Laboratories International news, Director James C. Foster sold 75,000 shares of Charles River Laboratories International stock in a transaction on Monday, June 29th. The stock was sold at an average price of $225.00, for a total transaction of $16,875,000.00. Following the sale, the director owned 31,596 shares of the company’s stock, valued at $7,109,100. The trade was a 70.36% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 1.30% of the stock is owned by insiders.

Charles River Laboratories International Price Performance

Shares of NYSE:CRL opened at $240.78 on Wednesday. The firm’s 50 day moving average is $202.05 and its two-hundred day moving average is $187.59. Charles River Laboratories International, Inc. has a 52 week low of $144.26 and a 52 week high of $242.73. The firm has a market capitalization of $11.60 billion, a P/E ratio of -64.04, a PEG ratio of 2.50 and a beta of 1.40. The company has a current ratio of 1.36, a quick ratio of 1.03 and a debt-to-equity ratio of 0.90.

Charles River Laboratories International (NYSE:CRL – Get Free Report) last released its quarterly earnings results on Thursday, May 7th. The medical research company reported $2.06 earnings per share for the quarter, beating analysts’ consensus estimates of $1.96 by $0.10. The company had revenue of $995.83 million for the quarter, compared to analysts’ expectations of $977.46 million. Charles River Laboratories International had a positive return on equity of 15.36% and a negative net margin of 4.59%.The business’s revenue for the quarter was up 1.2% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.34 earnings per share. Charles River Laboratories International has set its FY 2026 guidance at 10.800-11.300 EPS. Analysts anticipate that Charles River Laboratories International, Inc. will post 11.05 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of equities analysts have commented on CRL shares. Citigroup restated a “buy” rating on shares of Charles River Laboratories International in a research note on Wednesday, July 8th. Morgan Stanley increased their price target on Charles River Laboratories International from $220.00 to $260.00 and gave the stock an “overweight” rating in a research report on Thursday, July 9th. Evercore restated an “outperform” rating and set a $220.00 price objective on shares of Charles River Laboratories International in a research report on Friday, May 8th. Sanford C. Bernstein set a $250.00 price objective on Charles River Laboratories International in a research report on Wednesday, July 1st. Finally, Barclays upped their price objective on Charles River Laboratories International from $210.00 to $220.00 and gave the stock an “overweight” rating in a research note on Friday, May 8th. Eleven investment analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $220.75.

View Our Latest Analysis on CRL

Charles River Laboratories International Profile

(Free Report)

Charles River Laboratories International, Inc is a leading provider of research models and preclinical and clinical support services for the pharmaceutical, biotechnology and medical device industries. The company’s core offerings include discovery, safety assessment, toxicology, and pathology services, as well as supply of laboratory animals and related diagnostics. Services extend across in vivo and in vitro testing, biologics testing, and support for advanced therapies, helping clients accelerate drug development from early discovery through regulatory submission.

Founded in 1947 in Wilmington, Massachusetts, Charles River has grown through strategic investments and acquisitions to establish a broad portfolio of capabilities.

Ranger Investment Management L.P. Makes New $12.20 Million Investment in Charles River Laboratories International, Inc. $CRL

Insiders Place Their Bets

Charles River Laboratories International Price Performance

Wall Street Analysts Forecast Growth

Charles River Laboratories International Profile

Further Reading

You might be interested in: